An Exposure-Response Perspective on the Clinical Dose of Pretomanid

Pretomanid was approved by the U.S. FDA, via the limited population pathway for antibacterial and antifungal drugs, as part of a three-drug regimen with bedaquiline and linezolid for the treatment of extensively drug-resistant and treatment-intolerant or nonresponsive multidrug-resistant tuberculosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Nedelman, Jerry R., Salinger, David H., Subramoney, Vishak, Woolson, Rob, Wade, Karen, Li, Mengchun, Everitt, Daniel, Mendel, Carl M., Spigelman, Mel
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927811/
https://www.ncbi.nlm.nih.gov/pubmed/33077660
http://dx.doi.org/10.1128/AAC.01121-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7927811/
https://www.ncbi.nlm.nih.gov/pubmed/33077660
http://dx.doi.org/10.1128/AAC.01121-20

Ejemplares similares